Cargando…
First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors
Cholesteryl pullulan (CHP) is a novel antigen delivery system. CHP and New York esophageal squamous cell carcinoma 1 (NY-ESO-1) antigen complexes (CHP-NY-ESO-1) present multiple epitope peptides to the MHC class I and II pathways. Adjuvants are essential for cancer vaccines. MIS416 is a non-toxic mi...
Autores principales: | Ishihara, Mikiya, Tono, Yasutaka, Miyahara, Yoshihiro, Muraoka, Daisuke, Harada, Naozumi, Kageyama, Shinichi, Sasaki, Takeshi, Hori, Yasuhide, Soga, Norihito, Uchida, Katsunori, Shiraishi, Taizo, Sato, Eiichi, Kanda, Hideki, Mizuno, Toshiro, Webster, Gill A., Ikeda, Hiroaki, Katayama, Naoyuki, Sugimura, Yoshiki, Shiku, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113205/ https://www.ncbi.nlm.nih.gov/pubmed/31980914 http://dx.doi.org/10.1007/s00262-020-02483-1 |
Ejemplares similares
-
MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours
por: Ishihara, Mikiya, et al.
Publicado: (2020) -
NY-ESO-1 antigen expression and immune response are associated with poor prognosis in MAGE-A4-vaccinated patients with esophageal or head/neck squamous cell carcinoma
por: Ueda, Shugo, et al.
Publicado: (2018) -
Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients
por: Kageyama, Shinichi, et al.
Publicado: (2013) -
Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells
por: Gong, Wenjie, et al.
Publicado: (2021) -
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome
por: Ishihara, Mikiya, et al.
Publicado: (2022)